amiodarone has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Williams, A | 1 |
Sarkar, S | 1 |
Cuddon, P | 1 |
Ttofi, EK | 1 |
Saiki, S | 1 |
Siddiqi, FH | 1 |
Jahreiss, L | 1 |
Fleming, A | 1 |
Pask, D | 1 |
Goldsmith, P | 1 |
O'Kane, CJ | 1 |
Floto, RA | 1 |
Rubinsztein, DC | 1 |
1 other study available for amiodarone and Akinetic-Rigid Variant of Huntington Disease
Article | Year |
---|---|
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
Topics: Animals; Autophagy; Calcium Channels, L-Type; Clonidine; Cyclic AMP; Humans; Huntington Disease; Imi | 2008 |